NBP in Adult Patients With Acute Ischemic Stroke (AIS)
Public ClinicalTrials.gov record NCT02905565. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Add-On to Standard Of-Care Study of n Butylphthalide (NBP) Softgel Capsules for Treatment of Mild to Moderate Acute Ischemic Stroke (AIS) in Adult Subjects
Study identification
- NCT ID
- NCT02905565
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- CSPC-NBP Pharmaceutical Co., Ltd.
- Industry
- Enrollment
- 177 participants
Conditions and interventions
Conditions
Interventions
- NBP Softgel Capsules Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 85 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 27, 2018
- Primary completion
- Aug 6, 2020
- Completion
- Aug 6, 2020
- Last update posted
- Sep 16, 2020
2018 – 2020
United States locations
- U.S. sites
- 21
- U.S. states
- 16
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigative Site | Los Angeles | California | 90027 | — |
| Investigative Site | Los Angeles | California | 90095 | — |
| Investigative Site | Jacksonville | Florida | 32209 | — |
| Investigative Site | Des Moines | Iowa | 50314 | — |
| Investigative Site | Louisville | Kentucky | 40202 | — |
| Investigative Site | Boston | Massachusetts | 02111 | — |
| Investigative Site | Golden Valley | Minnesota | 55422 | — |
| Investigative Site | St Louis | Missouri | 63110 | — |
| Investigative Site | Omaha | Nebraska | 68123 | — |
| Investigative Site | Buffalo | New York | 14202 | — |
| Investigative Site | Asheville | North Carolina | 28801 | — |
| Investigative Site | Columbus | Ohio | 43210 | — |
| Investigative Site | Hillsboro | Oregon | 97123 | — |
| Investigative Site | Portland | Oregon | 97213 | — |
| Investigative Site | Portland | Oregon | 97225 | — |
| Investigative Site | Portland | Oregon | 97239 | — |
| Investigative Site | Philadelphia | Pennsylvania | 19104 | — |
| Investigative Site | Charleston | South Carolina | 29425 | — |
| Investigative Site | Columbia | South Carolina | 29203 | — |
| Investigative Site | Chattanooga | Tennessee | 37403 | — |
| Investigative Site | Burlington | Vermont | 05401 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02905565, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 16, 2020 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02905565 live on ClinicalTrials.gov.